{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T21:53:23Z","timestamp":1774648403720,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T00:00:00Z","timestamp":1668211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T00:00:00Z","timestamp":1668211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Arcutis Biotherapeutics, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s40257-022-00739-3","type":"journal-article","created":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T15:03:02Z","timestamp":1668265382000},"page":"305-313","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Effect of Roflumilast Cream (ARQ-151) on Itch and Itch-Related Sleep Loss in Adults with Chronic Plaque Psoriasis: Patient-Reported Itch Outcomes of a Phase 2b Trial"],"prefix":"10.1007","volume":"24","author":[{"given":"Linda","family":"Stein Gold","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Alonso-Llamazares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoe D.","family":"Draelos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melinda J.","family":"Gooderham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven E.","family":"Kempers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leon H.","family":"Kircik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark G.","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim A.","family":"Papp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Pariser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darryl P.","family":"Toth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gil","family":"Yosipovitch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert C.","family":"Higham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R.","family":"Berk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,12]]},"reference":[{"key":"739_CR1","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1111\/jdv.15450","volume":"33","author":"B Elewski","year":"2019","unstructured":"Elewski B, Alexis AF, Lebwohl M, Stein Gold L, Pariser D, Del Rosso J, et al. Itch: an under-recognized problem in psoriasis. J Eur Acad Dermatol Venereol. 2019;33:1465\u201376. https:\/\/doi.org\/10.1111\/jdv.15450.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"739_CR2","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/1477-7525-7-62","volume":"7","author":"D Globe","year":"2009","unstructured":"Globe D, Bayliss MS, Harrison DJ. The impact of itch symptoms in psoriasis: results from physician interviews and patient focus groups. Health Qual Life Outcomes. 2009;7:62. https:\/\/doi.org\/10.1186\/1477-7525-7-62.","journal-title":"Health Qual Life Outcomes"},{"key":"739_CR3","volume-title":"Global report on psoriasis","author":"World Health Organization","year":"2016","unstructured":"World Health Organization. Global report on psoriasis. Geneva: World Health Organization; 2016."},{"key":"739_CR4","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/ajd.12747","volume":"59","author":"P Dickison","year":"2018","unstructured":"Dickison P, Swain G, Peek JJ, Smith SD. Itching for answers: prevalence and severity of pruritus in psoriasis. Australas J Dermatol. 2018;59:206\u20139. https:\/\/doi.org\/10.1111\/ajd.12747.","journal-title":"Australas J Dermatol"},{"key":"739_CR5","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1001\/archderm.124.7.1052","volume":"124","author":"MA Gupta","year":"1988","unstructured":"Gupta MA, Gupta AK, Kirkby S, Weiner HK, Mace TM, Schork NJ, et al. Pruritus in psoriasis. A prospective study of some psychiatric and dermatologic correlates. Arch Dermatol. 1988;124:1052\u20137. https:\/\/doi.org\/10.1001\/archderm.124.7.1052.","journal-title":"Arch Dermatol"},{"key":"739_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2147\/ccid.s4465","volume":"2","author":"F Prignano","year":"2009","unstructured":"Prignano F, Ricceri F, Pescitelli L, Lotti T. Itch in psoriasis: epidemiology, clinical aspects and treatment options. Clin Cosmet Investig Dermatol. 2009;2:9\u201313. https:\/\/doi.org\/10.2147\/ccid.s4465.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"739_CR7","doi-asserted-by":"publisher","first-page":"257","DOI":"10.2340\/00015555-0851","volume":"90","author":"A Reich","year":"2010","unstructured":"Reich A, Hrehor\u00f3w E, Szepietowski JC. Pruritus is an important factor negatively influencing the well-being of psoriatic patients. Acta Derm Venereol. 2010;90:257\u201363. https:\/\/doi.org\/10.2340\/00015555-0851.","journal-title":"Acta Derm Venereol"},{"key":"739_CR8","volume-title":"Itch: mechanisms and treatment. Frontiers in Neuroscience","author":"A Reich","year":"2014","unstructured":"Reich A, Szepietowski JC. Clinical aspects of itch: psoriasis. In: Carstens E, Akiyama T, editors. Itch: mechanisms and treatment. Frontiers in Neuroscience. Boca Raton: CRC Press\/Taylor & Francis; 2014."},{"key":"739_CR9","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1046\/j.1365-2133.2000.03829.x","volume":"143","author":"G Yosipovitch","year":"2000","unstructured":"Yosipovitch G, Goon A, Wee J, Chan YH, Goh CL. The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis. Br J Dermatol. 2000;143:969\u201373. https:\/\/doi.org\/10.1046\/j.1365-2133.2000.03829.x.","journal-title":"Br J Dermatol"},{"key":"739_CR10","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1016\/j.jid.2021.02.743","volume":"141","author":"D Yan","year":"2021","unstructured":"Yan D, Blauvelt A, Dey AK, Golpanian RS, Hwang ST, Mehta NN, et al. New frontiers in psoriatic disease research, part II: comorbidities and targeted therapies. J Investig Dermatol. 2021;141:2328\u201337. https:\/\/doi.org\/10.1016\/j.jid.2021.02.743.","journal-title":"J Investig Dermatol"},{"key":"739_CR11","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.jaad.2020.07.087","volume":"84","author":"CA Elmets","year":"2021","unstructured":"Elmets CA, Korman NJ, Prater EF, Wong EB, Rupani RN, Kivelevitch D, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol. 2021;84:432\u201370. https:\/\/doi.org\/10.1016\/j.jaad.2020.07.087.","journal-title":"J Am Acad Dermatol"},{"key":"739_CR12","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.cellsig.2016.01.007","volume":"28","author":"PH Schafer","year":"2016","unstructured":"Schafer PH, Truzzi F, Parton A, Wu L, Kosek J, Zhang LH, et al. Phosphodiesterase 4 in inflammatory diseases: effects of apremilast in psoriatic blood and in dermal myofibroblasts through the PDE4\/CD271 complex. Cell Signal. 2016;28:753\u201363. https:\/\/doi.org\/10.1016\/j.cellsig.2016.01.007.","journal-title":"Cell Signal"},{"key":"739_CR13","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1124\/jpet.116.232819","volume":"358","author":"C Dong","year":"2016","unstructured":"Dong C, Virtucio C, Zemska O, Baltazar G, Zhou Y, Baia D, et al. Treatment of skin inflammation with benzoxaborole phosphodiesterase inhibitors: selectivity, cellular activity, and effect on cytokines associated with skin inflammation and skin architecture changes. J Pharmacol Exp Ther. 2016;358:413\u201322. https:\/\/doi.org\/10.1124\/jpet.116.232819.","journal-title":"J Pharmacol Exp Ther"},{"key":"739_CR14","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.3389\/fphar.2018.01048","volume":"9","author":"H Li","year":"2018","unstructured":"Li H, Zuo J, Tang W. Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases. Front Pharmacol. 2018;9:1048. https:\/\/doi.org\/10.3389\/fphar.2018.01048.","journal-title":"Front Pharmacol"},{"key":"739_CR15","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.jdermsci.2014.10.005","volume":"76","author":"T Andoh","year":"2014","unstructured":"Andoh T, Kuraishi Y. Antipruritic mechanisms of topical E6005, a phosphodiesterase 4 inhibitor: inhibition of responses to proteinase-activated receptor 2 stimulation mediated by increase in intracellular cyclic AMP. J Dermatol Sci. 2014;76:206\u201313. https:\/\/doi.org\/10.1016\/j.jdermsci.2014.10.005.","journal-title":"J Dermatol Sci"},{"key":"739_CR16","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/exd.12377","volume":"23","author":"T Andoh","year":"2014","unstructured":"Andoh T, Yoshida T, Kuraishi Y. Topical E6005, a novel phosphodiesterase 4 inhibitor, attenuates spontaneous itch-related responses in mice with chronic atopy-like dermatitis. Exp Dermatol. 2014;23:359\u201361. https:\/\/doi.org\/10.1111\/exd.12377.","journal-title":"Exp Dermatol"},{"key":"739_CR17","doi-asserted-by":"publisher","first-page":"36","DOI":"10.2340\/00015555-3347","volume":"100","author":"E Fowler","year":"2020","unstructured":"Fowler E, Yosipovitch G. A new generation of treatments for itch. Acta Derm Venereol. 2020;100:36\u201344. https:\/\/doi.org\/10.2340\/00015555-3347.","journal-title":"Acta Derm Venereol"},{"key":"739_CR18","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s13555-018-0267-9","volume":"8","author":"G Yosipovitch","year":"2018","unstructured":"Yosipovitch G, Reich A, Steinhoff M, Beselin A, Kent T, Dossenbach M, et al. Impact of ixekizumab treatment on itch and Psoriasis Area and Severity Index in patients with moderate-to-severe plaque psoriasis: an integrated analysis of two Phase III randomized studies. Dermatol Ther (Heidelb). 2018;8:621\u201337. https:\/\/doi.org\/10.1007\/s13555-018-0267-9.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"739_CR19","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1124\/jpet.113.205542","volume":"346","author":"N Ishii","year":"2013","unstructured":"Ishii N, Shirato M, Wakita H, Miyazaki K, Takase Y, Asano O, et al. Antipruritic effect of the topical phosphodiesterase 4 inhibitor E6005 ameliorates skin lesions in a mouse atopic dermatitis model. J Pharmacol Exp Ther. 2013;346:105\u201312. https:\/\/doi.org\/10.1124\/jpet.113.205542.","journal-title":"J Pharmacol Exp Ther"},{"key":"739_CR20","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/1477-7525-11-82","volume":"11","author":"V Strand","year":"2013","unstructured":"Strand V, Fiorentino D, Hu C, Day RM, Stevens RM, Papp KA. Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a Phase IIb randomized, controlled study. Health Qual Life Outcomes. 2013;11:82. https:\/\/doi.org\/10.1186\/1477-7525-11-82.","journal-title":"Health Qual Life Outcomes"},{"key":"739_CR21","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/exd.12606","volume":"24","author":"H Wakita","year":"2015","unstructured":"Wakita H, Ohkuro M, Ishii N, Hishinuma I, Shirato M. A putative antipruritic mechanism of the phosphodiesterase-4 inhibitor E6005 by attenuating capsaicin-induced depolarization of C-fibre nerves. Exp Dermatol. 2015;24:215\u20136. https:\/\/doi.org\/10.1111\/exd.12606.","journal-title":"Exp Dermatol"},{"key":"739_CR22","volume-title":"OTEZLA (apremilast) prescribing information","author":"Amgen Inc.","year":"2020","unstructured":"Amgen Inc. OTEZLA (apremilast) prescribing information. Thousand Oaks: Amgen Inc.; 2020."},{"key":"739_CR23","volume-title":"EUCRISA (crisaborole) prescribing information","author":"Pfizer Labs","year":"2020","unstructured":"Pfizer Labs. EUCRISA (crisaborole) prescribing information. New York: Pfizer Labs; 2020."},{"key":"739_CR24","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1056\/NEJMoa2000073","volume":"383","author":"MG Lebwohl","year":"2020","unstructured":"Lebwohl MG, Papp KA, Stein Gold L, Gooderham MJ, Kircik LH, Draelos ZD, et al. Trial of roflumilast cream for chronic plaque psoriasis. N Engl J Med. 2020;383:229\u201339. https:\/\/doi.org\/10.1056\/NEJMoa2000073.","journal-title":"N Engl J Med"},{"key":"739_CR25","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s13555-021-00572-2","volume":"11","author":"KA Papp","year":"2021","unstructured":"Papp KA, Lebwohl MG, Kircik LH, Pariser DM, Strober B, Krueger GG, et al. The proposed PASI-HD provides more precise assessment of plaque psoriasis severity in anatomical regions with a low area score. Dermatol Ther (Heidelb). 2021;11:1079\u201383. https:\/\/doi.org\/10.1007\/s13555-021-00572-2.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"739_CR26","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/bjd.14464","volume":"175","author":"AB Kimball","year":"2016","unstructured":"Kimball AB, Naegeli AN, Edson-Heredia E, Lin CY, Gaich C, Nika\u00ef E, et al. Psychometric properties of the Itch Numeric Rating Scale in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016;175:157\u201362. https:\/\/doi.org\/10.1111\/bjd.14464.","journal-title":"Br J Dermatol"},{"key":"739_CR27","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1111\/ijd.12645","volume":"54","author":"AN Naegeli","year":"2015","unstructured":"Naegeli AN, Flood E, Tucker J, Devlen J, Edson-Heredia E. The Worst Itch Numeric Rating Scale for patients with moderate to severe plaque psoriasis or psoriatic arthritis. Int J Dermatol. 2015;54:715\u201322. https:\/\/doi.org\/10.1111\/ijd.12645.","journal-title":"Int J Dermatol"},{"key":"739_CR28","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1111\/j.1365-4632.2012.05798.x","volume":"53","author":"M Lebwohl","year":"2014","unstructured":"Lebwohl M, Swensen AR, Nyirady J, Kim E, Gwaltney CJ, Strober BE. The Psoriasis Symptom Diary: development and content validity of a novel patient-reported outcome instrument. Int J Dermatol. 2014;53:714\u201322. https:\/\/doi.org\/10.1111\/j.1365-4632.2012.05798.x.","journal-title":"Int J Dermatol"},{"key":"739_CR29","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jval.2013.07.002","volume":"16","author":"BE Strober","year":"2013","unstructured":"Strober BE, Nyirady J, Mallya UG, Guettner A, Papavassilis C, Gottlieb AB, et al. Item-level psychometric properties for a new patient-reported psoriasis symptom diary. Value Health. 2013;16:1014\u201322. https:\/\/doi.org\/10.1016\/j.jval.2013.07.002.","journal-title":"Value Health"},{"key":"739_CR30","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210\u20136. https:\/\/doi.org\/10.1111\/j.1365-2230.1994.tb01167.x.","journal-title":"Clin Exp Dermatol"},{"key":"739_CR31","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2340\/00015555-3065","volume":"99","author":"K Kaaz","year":"2019","unstructured":"Kaaz K, Szepietowski JC, Matusiak \u0141. Influence of itch and pain on sleep quality in atopic dermatitis and psoriasis. Acta Derm Venereol. 2019;99:175\u201380. https:\/\/doi.org\/10.2340\/00015555-3065.","journal-title":"Acta Derm Venereol"},{"key":"739_CR32","doi-asserted-by":"publisher","first-page":"124","DOI":"10.5152\/eurasianjmed.2017.17132","volume":"49","author":"M Melikoglu","year":"2017","unstructured":"Melikoglu M. Sleep quality and its association with disease severity in psoriasis. Eurasian J Med. 2017;49:124\u20137. https:\/\/doi.org\/10.5152\/eurasianjmed.2017.17132.","journal-title":"Eurasian J Med"},{"key":"739_CR33","doi-asserted-by":"publisher","first-page":"4081","DOI":"10.3390\/jcm10184081","volume":"10","author":"PC Taylor","year":"2021","unstructured":"Taylor PC, Bushmakin AG, Cappelleri JC, Young P, Germino R, Merola JF, et al. Itch as major mediator of effect of tofacitinib on health-related quality of life in psoriatic arthritis: a mediation analysis. J Clin Med. 2021;10:4081. https:\/\/doi.org\/10.3390\/jcm10184081.","journal-title":"J Clin Med"},{"key":"739_CR34","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jaad.2013.09.030","volume":"70","author":"D Roblin","year":"2014","unstructured":"Roblin D, Wickramasinghe R, Yosipovitch G. Pruritus severity in patients with psoriasis is not correlated with psoriasis disease severity. J Am Acad Dermatol. 2014;70:390\u20131. https:\/\/doi.org\/10.1016\/j.jaad.2013.09.030.","journal-title":"J Am Acad Dermatol"},{"key":"739_CR35","doi-asserted-by":"publisher","first-page":"8406","DOI":"10.3390\/ijms21218406","volume":"21","author":"E Komiya","year":"2020","unstructured":"Komiya E, Tominaga M, Kamata Y, Suga Y, Takamori K. Molecular and cellular mechanisms of itch in psoriasis. Int J Mol Sci. 2020;21:8406. https:\/\/doi.org\/10.3390\/ijms21218406.","journal-title":"Int J Mol Sci"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-022-00739-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-022-00739-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-022-00739-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,25]],"date-time":"2023-02-25T05:37:39Z","timestamp":1677303459000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-022-00739-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,12]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["739"],"URL":"https:\/\/doi.org\/10.1007\/s40257-022-00739-3","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,12]]},"assertion":[{"value":"16 October 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by Arcutis Biotherapeutics, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The trial was conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice guidelines of the International Council for Harmonisation and is registered on ClinicalTrials.gov (NCT03638258). Reviewed and approved by the Aspire Institutional Review Board for US sites, the Western Institutional Review Board for sites in Canada, and local institutional review boards for sites not covered by these central institutional review boards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and compliance with ethical standards"}},{"value":"L. Stein Gold is an investigator for AbbVie, Arcutis, Amgen, Dermavant, Eli Lilly and Company, Leo, Novartis, Ortho Derm, and Pfizer; serves as an advisor for Amgen, Arcutis, BMS, Dermavant, Leo, Novartis, Ortho Derm, Pfizer, and UCB, is a speaker for Amgen, Leo, Ortho Derm, and Pfizer. J. Alonso-Llamazares is an investigator for Arcutis; speaker for Celgene (Amgen), Dermira (Eli Lilly), Eli Lilly and Company, Ortho Derm, and UCB Pharma; and serves on advisory boards for Leo. Z.D. Draelos received grant support from Arcutis Biotherapeutics, Inc. for the conduct of this study. M.J. Gooderham has been a speaker, advisory board member, investigator and\/or consultant for AbbVie, Akros, Amgen, Arcutis, BMS, Boehringer-Ingelheim, Celgene, Dermavant, Dermira, Eli Lilly and Company, Galderma, GSK, Incyte, Janssen, Kyowa Kirin, LEO Pharma, Medimmune, Merck, Novartis, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, UCB Pharma, and Valeant\/Bausch. S.E. Kempers is an investigator for Arcutis Biotherapeutics, Inc., and serves as a consultant for Foamix and Kinex. L.H. Kircik is an investigator, consultant, speaker, and\/or advisory board member for Abbott Laboratories, Acambis, Aclaris, Allergan, Inc., Almirall, Amgen Inc., Anacor Pharmaceuticals, Assos Pharma, Astellas Pharma US, Inc., Asubio, Berlex Laboratories (Bayer HealthCare Pharmaceuticals), Biogen-Idec, Biolife, Biopelle, Boehringer-Ingelheim, Breckinridge Pharma, Celgene, Cellceutix, Centocor, Inc., Cipher, Coherus, Colbar, CollaGenex, Combinatrix, Connetics Corporation, Coria, Dermavant, Dermik Laboratories, Dermira, Dow Pharmaceutical Sciences, Inc., Dusa, Eli Lilly and Company, Embil Pharmaceuticals, EOS, Exeltis, Ferndale Laboratories, Inc., Foamix, Genentech, Inc., GlaxoSmithKline, PLC, Health Point, LTD, Idera, Innocutis, Innovail, Intendis, Isdin, Johnson & Johnson, Laboratory Skin Care Inc., Leo, L'Oreal, 3M, Maruho, Medical International Technologies, Medicis Pharmaceutical Corp., Merck, Merz, Nano Bio, Novartis AG, Noven Pharmaceuticals, Nucryst Pharmaceuticals Corp., Obagi, Onset, OrthoNeutrogena, PediaPharma, PharmaDerm, Pfizer, Promius, PuraCap, QLT, Inc., Quinnova, Quatrix, Serono (Merck Serono International SA), SkinMedica, Inc., Stiefel Laboratories, Inc., Sun Pharma, Taro, TolerRx, Triax, UCB Pharma, Valeant Pharmaceuticals Intl, Warner-Chilcott, XenoPort, and ZAGE. M.G. Lebwohl reports receipt of research funds from AbbVie, Amgen, Arcutis, Boehringer-Ingelheim, Dermavant, Eli Lilly and Company, Incyte, Janssen Research & Development, LLC, Leo Pharma, Ortho Dermatologics, Pfizer, and UCB Pharma and serves as a consultant for Aditum Bio, Allergan, Almirall, Arcutis, Inc., Avotres Therapeutics, BirchBioMed Inc., BMD Skincare, Boehringer-Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Corrona, Dermavant Sciences, Evelo, Facilitate International Dermatologic Education, Foundation for Research and Education in Dermatology, Inozyme Pharma, LEO Pharma, Meiji Seika Pharma, Menlo, Mitsubishi, Neuroderm, Pfizer, Promius\/Dr. Reddy\u2019s Laboratories, Serono, Theravance, and Verrica. K.A. Papp is an investigator, consultant, speaker, scientific officer or has served on steering committees or advisory boards for AbbVie, Akros, Amgen, Anacor, Arcutis, Astellas, Avillion, Bausch Health\/Valeant, Baxalta, Boehringer-Ingelheim, Bristol Myers Squibb, Can-Fite Biopharma, Celgene, Coherus, Dermavant, Dermira, Dice Pharmaceuticals, Dow Pharma, Eli Lilly and Company, Evelo, Galapagos, Galderma, Gilead, GSK, Incyte, Janssen, Kyowa Hakko Kirin, Leo, Medimmune, Meiji Seika Pharma, Merck (MSD), Merck Serono, Mitsubishi Pharma, Moberg Pharma, Novartis, Pfizer, PRCL Research, Regeneron, Roche, Sanofi-Aventis\/Genzyme, Sun Pharma, Takeda, UCB, and Xencor. D.M. Pariser is an investigator, consultant, and\/or advisory board member for Abbott Laboratories, Almirall, Amgen, AOBiome, LLC, Asana Biosciences, LLC, Atacama Therapeutics, Bickel Biotechnology, Biofrontera AG, BMS, Celgene Corporation, Dermavant Sciences, Dermira, Eli Lilly and Company, LEO Pharma, US, Menlo Therapeutics, Merck & Co., Inc, Novartis Pharmaceuticals Corp., Novo Nordisk A\/S, Ortho Dermatologics, Pfizer Inc., Regeneron, Sanofi, Stiefel, a GSK company, TDM SurgiTech, Inc., TheraVida, and Valeant Pharmaceuticals International. D.P. Toth is an investigator and\/or consultant for AbbVie, Amgen, Arcutis, Avillion, Bausch Health\/Valeant, Bristol Myers Squibb, Boehringer-Ingelheim, Celgene, Dermira, Eli Lilly and Company, Galderma, Genentech, GSK, Incyte, Janssen, Leo Pharma, Merck Serono, Medimmune, Novartis, Pfizer, Regeneron, Roche, Sanofi-Aventis\/Genzyme, Sun Pharma, and UCB Pharma. G. Yosipovitch has received grant\/research support from Bellus Health, Galderma, Kiniksa, Leo Pharma, Novartis, Pfizer Inc., and Sanofi Regeneron and has been a consultant for Bellus Health, Eli Lilly and Company, Galderma, Kiniksa, Leo Pharma, Novartis, Pfizer Inc., Sanofi Regeneron, and Trevi. R. Higham, A. Feng, and D.R. Berk are employees of Arcutis Biotherapeutics, Inc.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Before enrollment of patients, the study protocol and informed consent form were reviewed and approved by an appropriate Institutional Review Board or Independent Ethics Committee. All patients provided written informed consent before screening.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data collected for this study will be made available to others. Proposals for data requests will be reviewed and considered for sharing following approval of the indication. Information about when data availability will begin and end will be provided following approval of the indication.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Authors had full access to all the data in the study and they all take responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: All authors. Acquisition, analysis, or interpretation of data: All authors. Drafting of the manuscript: All authors. Critical revision of the manuscript for important intellectual content: All authors. Statistical analysis: Feng. Supervision: Higham, Berk.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}